We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Regeneron has partnered with the University of Pennsylvania (UPenn) to develop a gene therapy nasal delivery system for its COVID-19 antibody cocktail, casirivimab and imdevimab, which received an Emergency Use Authorization from the FDA last month for mild-to-moderately ill coronavirus patients at high risk. Read More
The global police organization Interpol issued a warning yesterday to countries to prepare for a new wave of organized criminal activity, including cyber hacking of drugmakers as governments prepare to ship their vaccines. Read More
Wren has pioneered a new approach to protein misfolding diseases that uses a predictive method in place of the traditional drug discovery and biological approaches. Read More
AstraZeneca is selling off limited rights to its former blockbuster statin drug Crestor to Grünenthal for $320 million upfront and possible future milestone payments of up to $30 million. Read More
Novavax said it will begin a delayed phase 3 trial in the U.S. and Mexico to evaluate its COVID-19 vaccine candidate, NVX-CoV2373, “in the coming weeks” and that its 15,000-person late-stage trial in the UK is now fully enrolled. Read More
United Biomedical’s nonprofit vaccine subsidiary, Covaxx, said it has secured supply deals worth $2.8 billion for more than 140 million doses of its COVID-19 vaccine candidate, UB-612, in “multiple countries,” including Brazil, Ecuador and Peru. Read More
Merck is expanding further into the biotech sector by acquiring Rockville, Md., biopharma company OncoImmune for $425 million, netting in the process an investigational drug that has shown promise as a treatment for hospitalized COVID-19 patients. Read More
As some of the world’s largest drugmakers gear up to manufacture and distribute COVID-19 vaccines, a relatively tiny competitor, Massachusetts-based Moderna, faces some unique challenges. Read More